Clinical Trial Agreement Smlouva o klinickém hodnoceníSeptember 23rd, 2021
FiledSeptember 23rd, 2021Trial Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B- cell lymphoma (DLBCL)